
zzso is a zzso zzso zzso zzso zzso with specificity for the zzso and zzso gamma zzso zzso zzso This zzso promotes the targeted zzso of zzso cells zzso the zzso gene product of the zzso zzso by human natural killer cells and zzso zzso expressing the zzso gamma zzso A zzso In a Phase I clinical trial of zzso 15 patients with zzso tumors were treated with 1 h zzso infusions of zzso on days 1, 4, 5, 6, 7, and 8 of a single course of zzso Three patients were treated with daily doses of zzso zzso while six patients each were treated with zzso zzso and zzso zzso zzso The principal zzso transient zzso were zzso zzso zzso zzso and zzso zzso was dose limiting at the zzso zzso dose level in two patients who had received extensive prior zzso zzso zzso zzso was zzso in serum following zzso administration, and its zzso binding properties were zzso The zzso of this zzso zzso were variable and best described by zzso zzso with an average zzso 1/2 of 20 zzso zzso zzso bound extensively to all zzso and to a proportion of zzso and zzso The initial zzso treatment induced more than zzso increases in circulating levels of tumor necrosis zzso zzso 6, and zzso 8 and lesser rises in zzso zzso factor and zzso zzso human zzso zzso responses were induced in 14 of 15 zzso Several minor clinical responses were observed, with reductions in the thickness of chest wall disease in one patient with zzso breast zzso Resolution of zzso zzso and zzso respectively, were noted in two patients with zzso colon cancer, and one of two liver zzso resolved in a patient with zzso colon zzso Treatment with zzso zzso has potent zzso zzso The maximum tolerated dose and Phase II daily dose for patients with extensive prior zzso chemotherapy was zzso zzso zzso dose escalation is required to identify the zzso tolerated dose for patients who have been less heavily zzso 

